INS and metabolic syndrome: These increased risks might be due to elevated estrogen levels that occur from enhanced aromatization in the adipose tissue and increases in the levels of mitogenic agents such as INS and/or IGF associated with obesity-related metabolic syndromes (DM and BC) (18).